Orforglipron Reference

Plain English

What it is

Orforglipron (brand name Foundayo) is a prescription weight-loss pill that the U.S. Food and Drug Administration (FDA) approved in April 2026. It is a GLP-1 medicine, the same drug family as the well-known GLP-1 shots, but it is a small molecule you swallow instead of inject. It does not require timing around meals or limiting water the way the older GLP-1 pill Rybelsus does.

What people use it for

It is approved for adults who have obesity, or who are overweight and also have a weight-related health problem, to help them lose weight and keep it off while eating fewer calories and being more active. The big draw is that it is a pill, with no injections and none of the empty-stomach water rules that the older GLP-1 pill Rybelsus requires.

What the science shows

In a large Phase 3 trial that ran more than a year in adults with obesity, people taking orforglipron lost a meaningful amount of weight compared with a dummy pill (placebo). That weight loss was smaller than what the injectable GLP-1 and dual-hormone weight drugs produce in their own trials. Separate diabetes trials found blood-sugar improvements in line with other GLP-1 drugs.

The catch

Like other GLP-1 medicines, it carries a boxed warning that it may cause tumors in the thyroid, including thyroid cancer, and the most common side effects are stomach and gut problems such as nausea, constipation, diarrhea, and vomiting. Because the FDA-approved product is the specific branded pill Foundayo, any orforglipron sold online or mixed by a compounding pharmacy is not that approved product.

Reference summary

Wharton 2025 NEJM (ATTAIN-1, Phase 3, adults with obesity, 72 weeks) reported approximately 11 percent mean weight loss at the highest dose - smaller than the magnitudes seen with injectable semaglutide and tirzepatide pivotal trials but meaningful for an oral, non-peptide product that does not require the food / water timing restrictions of oral semaglutide (Rybelsus). Phase 3 ACHIEVE trials in type 2 diabetes reported A1c reductions broadly consistent with the GLP-1 class. The principal practical advantage of orforglipron is the oral non-peptide formulation; the principal practical tradeoff versus injectable analogs is a somewhat smaller magnitude of effect.

Regulatory and posture

Categories

GLP-1, Fat Loss

Aliases

LY3502970, Oral non-peptide small-molecule GLP-1 receptor agonist

Evidence posture

human

Regulatory status

FDA-approved. The FDA approved Foundayo (orforglipron), Eli Lilly's oral non-peptide small-molecule GLP-1 receptor agonist, on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. Unlike oral semaglutide (Rybelsus), it can be taken at any time of day without food or water restrictions. The Phase 3 development program was ACHIEVE (type 2 diabetes) and ATTAIN (obesity).

Content review status

label verified

Related tools

• Semaglutide dose calculator - Run semaglutide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.